Simplex Trading
ALLO icon

Simplex Trading’s Allogene Therapeutics ALLO Stock Holding History

Simplex Trading’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.5K Buy
31,000
+3,200
+12% +$7.03K ﹤0.01% 6036
2026
Q1 		$67.8K Buy
27,800
+25,000
+893% +$50.1K ﹤0.01% 5525
2025
Q4 		$3.84K Sell
2,800
-300
-10% -$396 ﹤0.01% 7561
2025
Q3 		$3K Sell
3,100
-17,200
-85% -$20.5K ﹤0.01% 8465
2025
Q2 		$22K Sell
20,300
-2,200
-10% -$2.92K ﹤0.01% 6669
2025
Q1 		$32K Sell
22,500
-7,300
-24% -$13.8K ﹤0.01% 6179
2024
Q4 		$63K Buy
29,800
+800
+3% +$1.97K ﹤0.01% 5622
2024
Q3 		$81K Buy
29,000
+21,000
+263% +$56K ﹤0.01% 5424
2024
Q2 		$18K Buy
8,000
+6,900
+627% +$20.4K ﹤0.01% 6965
2024
Q1 		$4K Buy
1,100
+600
+120% +$2.5K ﹤0.01% 8077
2023
Q4 		$1K Buy
+500
New +$1.42K ﹤0.01% 8424
2023
Q2 		– Sell
-134,900
Closed -$666K – 8869
2023
Q1 		$666K Buy
134,900
+134,200
+19,171% +$861K ﹤0.01% 2986
2022
Q4 		$4K Sell
700
-11,300
-94% -$105K ﹤0.01% 8161
2022
Q3 		$129K Buy
12,000
+11,600
+2,900% +$158K ﹤0.01% 5179
2022
Q2 		$4K Sell
400
-1,000
-71% -$8.88K ﹤0.01% 8919
2022
Q1 		$12K Sell
1,400
-600
-30% -$6.25K ﹤0.01% 8712
2021
Q4 		$29K Sell
2,000
-6,200
-76% -$109K ﹤0.01% 7925
2021
Q3 		$217K Hold
8,200
– – ﹤0.01% 5464
2021
Q2 		$213K Buy
8,200
+8,192
+102,400% +$234K ﹤0.01% 5576
2021
Q1 		$28K Buy
8
+1
+14% +$34 ﹤0.01% 7170
2020
Q4 		$17K Buy
7
+6
+600% +$196 ﹤0.01% 7065
2020
Q3 		$3K Sell
1
-77
-99% -$2.9K ﹤0.01% 7260
2020
Q2 		$333K Buy
78
+49
+169% +$1.77K ﹤0.01% 3404
2020
Q1 		$56K Sell
29
-182
-86% -$4.33K ﹤0.01% 5006
2019
Q4 		$548K Buy
211
+178
+539% +$4.9K ﹤0.01% 2654
2019
Q3 		$89K Buy
33
+13
+65% +$370 ﹤0.01% 4444
2019
Q2 		$53K Sell
20
-265
-93% -$7.38K ﹤0.01% 4795
2019
Q1 		$823K Buy
285
+279
+4,650% +$8.1K ﹤0.01% 2163
2018
Q4 		$16K Buy
+6
New +$159 ﹤0.01% 5496

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Simplex Trading's ALLO Position: Q2 2026 in Review

Simplex Trading sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 53,282 shares — an estimated $117K sold.

Simplex Trading first reported a position in ALLO in Q4 2018 and held it in 20 quarters. The position peaked at $730K in Q1 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Simplex Trading reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplex Trading sold 53,282 Allogene Therapeutics shares in Q2 2026, an estimated $117K.
  • Simplex Trading first reported a position in Allogene Therapeutics in Q4 2018 and held it in 20 quarters.
  • Simplex Trading's Allogene Therapeutics position peaked at $730K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.